Catheter-based clot-dissolving drug for intermediate-high risk pulmonary embolism
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests whether a standard procedure using a catheter to deliver clot-dissolving medicine directly into the lung artery works well for people with a serious but not immediately life-threatening blood clot in the lungs (pulmonary embolism). It aims to improve heart function and reduce long-term complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a blood clot in the main or large branches of the lung artery within the last 14 days.
- Your pulmonary embolism is considered intermediate-high risk, meaning your heart is strained (seen on an imaging test) and a blood test shows elevated heart stress markers.
- You do not have any condition that makes clot-dissolving medication unsafe, such as recent stroke, major bleeding, severe high blood pressure, or recent surgery.
- You are not pregnant, breastfeeding, or allergic to the study drugs.
- You do not have a serious active cancer or other major health issues listed in the exclusion criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two ways to treat a large blood clot in the lungs that is causing life-threatening symptoms. One method uses a device to remove the clot, the other uses medicine to dissolve it.
This study looks at how well a catheter (a thin tube) works to treat a serious type of blood clot in the lungs. It is for people who have a large clot that is causing problems like fast heart rate or low blood pressure.
This trial compares a lower dose of the clot-dissolving medicine alteplase to the standard full dose for people with a severe pulmonary embolism (a blood clot in the lungs). The goal is to see if the lower dose is just as safe and effective, with fewer bleeding risks.
This trial tests a treatment that uses ultrasound to guide a thin tube (catheter) to deliver clot-busting medicine directly into the blood clot in your lung. It may be an option for people whose clot is serious but not yet causing shock, and who have symptoms that started within the last two weeks.
This study tests a new catheter-based device that delivers clot-dissolving medicine directly to the blood clot in the lungs for people with a moderate-risk pulmonary embolism. The goal is to improve blood flow to the lungs and relieve symptoms with a lower dose of medication than standard care.
This trial tests a procedure that uses ultrasound to guide a catheter that delivers clot-dissolving medicine directly to a blood clot in the lungs. It is for people who have a pulmonary embolism that causes some heart strain but who are not in shock.
Hear when a new Pulmonary Embolism Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.